XKRX
096530
Market cap1.30bUSD
Oct 08, Last price
38,150.00KRW
1D
-1.93%
1Q
31.55%
Jan 2017
9.16%
IPO
-1.84%
Name
Seegene Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Key people
Internal Auditor · since 2023
Yeong Seok Baek
Assistant Managing Director · since 2022
Jun Yong Ha
Assistant Managing Director · since 2021
Jae Jong Han
Assistant Managing Director · since 2020
Jeong Beom Kim
Assistant Managing Director · since 2024
Hong Ho Kim
Assistant Managing Director · since 2024
Bong Ho Kim
Assistant Managing Director · since 2022
Yun Ji Kim
Assistant Managing Director · since 2022
Jeong Gu Kim
Assistant Managing Director · since 2021
Myeong Yil Kim
Assistant Managing Director · since 2024
Yeong Jo Lee
Assistant Managing Director · since 2022
Jik Yeong Park
Assistant Managing Director · since 2021
Dong Heon Shin
Assistant Managing Director · since 2024
Jin Su Choi
Co-President, Director · since 2024
Dae Hun Lee
Co-President, Co-Chief Executive Officer, Director · since 2024
Gyeong Jun Cheon
Other Non-Executive Director · since 2021
Hyeon Cheol Jung
Non-Executive Independent Director · since 2022
Chang Se Lee
Non-Executive Independent Director · since 2020
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||